Targeting specific proteins to combat treatment resistance in advanced prostate cancer
Targeting FOXA2/AP-1 axis to overcome lineage plasticity and therapy resistance in castration-resistant prostate cancer
This study is looking at how two specific proteins help advanced prostate cancer become resistant to standard hormone treatments, with the goal of finding new ways to effectively treat patients who are struggling with this tough condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Massachusetts Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11100274 on NIH RePORTER |
What this research studies
This research investigates how certain proteins, specifically FOXA2 and AP-1, contribute to the development of resistance in advanced prostate cancer that no longer responds to standard hormone therapies. By understanding the mechanisms that allow cancer cells to change and adapt, the study aims to identify new therapeutic strategies that can effectively target these resistant cancer cells. The approach involves examining how these proteins interact with the cancer cell's genetic material to promote survival and growth despite treatment. Patients may benefit from insights that could lead to more effective treatments for advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer, particularly those who have developed resistance to androgen receptor-targeted therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat advanced prostate cancer that has become resistant to current treatments.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Boston, United States
- University of Massachusetts Boston — Boston, United States (Active)
Researchers
- Principal investigator: Cai, Changmeng — University of Massachusetts Boston
- Study coordinator: Cai, Changmeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.